← Scroll for more →
Myriad Genetics Inc (MYGN)
In Vitro & In Vivo Diagnostic Substances
Latest Price
$6.35
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
3.22
P/B Ratio
1.97
Valuation metrics
adjust assumptions →Base FCF: $200,000 (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$0.35
94% downside
Institutional Ownership
91.6% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10.89M | $62.0M | 11.39% | +2.00M | 2026-06-30 |
| Millennium Management LLC | 6.62M | $37.0M | 6.93% | -48.4K | 2026-06-30 |
| Vestal Point Capital, LP | 5.74M | $32.0M | 6.00% | +4.09M | 2026-06-30 |
| State Street Corp | 4.99M | $28.0M | 5.21% | +561.0K | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 4.58M | $26.0M | 4.79% | +82.4K | 2026-06-30 |
| Vanguard Capital Management LLC | 4.08M | $23.0M | 4.27% | +156.9K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 3.08M | $17.0M | 3.22% | +497.4K | 2026-06-30 |
| AQR Capital Management LLC | 2.77M | $15.0M | 2.89% | +854.4K | 2026-06-30 |
| Morgan Stanley | 2.48M | $14.0M | 2.60% | -687.6K | 2026-06-30 |
| Geode Capital Management, LLC | 2.42M | $13.0M | 2.53% | +96.8K | 2026-06-30 |